Moleculin Biotech
MBRX
13 hedge funds and large institutions have $2.45M invested in Moleculin Biotech in 2020 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
8% more funds holding
Funds holding: 12 → 13 (+1)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
1.47% less ownership
Funds ownership: 6.36% → 4.88% (-1.5%)
56% less capital inflows, than outflows
Capital inflows: $595K | Capital outflows: $1.36M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$298K |
| 2 |
Millennium Management
New York
|
+$213K |
| 3 |
ETrade Capital Management
Arlington,
Virginia
|
+$42.5K |
| 4 |
Truist Financial
Charlotte,
North Carolina
|
+$42.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$850K |
| 2 |
Renaissance Technologies
New York
|
-$425K |
| 3 |
Paloma Partners
Greenwich,
Connecticut
|
-$34K |
| 4 |
HCR Wealth Advisors
Los Angeles,
California
|
-$14K |
| 5 |
Squarepoint
New York
|
-$11K |
MBRX Hedge Fund Activity: Q3 2020 in Review
13 of the 4,972 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q3 2020, worth a combined $2.45M — down 34% from $3.71M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new MBRX positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Qube Research & Technologies (QRT), adding an estimated $298K. The largest seller was Vanguard Group, cutting an estimated $850K.
- 13 institutional investors held Moleculin Biotech (MBRX) as of Q3 2020, up from 12 in Q2 2020.
- Funds reported $2.45M of Moleculin Biotech stock for Q3 2020, down 34% quarter-over-quarter.
- 2 funds opened new Moleculin Biotech positions in Q3 2020 and 1 closed out, a net change of +1 holder.
- The largest Moleculin Biotech buyer in Q3 2020 was Qube Research & Technologies (QRT), an estimated $298K added.
- The largest Moleculin Biotech seller in Q3 2020 was Vanguard Group, an estimated $850K sold.
Based on aggregated 13F filings for Q3 2020.